Arix Bioscience PLC: Artios announces collaboration with Novartis to create next generation DDR cancer therapies
DJ Artios announces collaboration with Novartis to create next generation DDR cancer therapies
Arix Bioscience PLC (ARIX)
Artios announces collaboration with Novartis to create next generation DDR cancer therapies
07-Apr-2021 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=
Arix Bioscience plc
Artios announces collaboration with Novartis to create next generation DDR cancer therapies - Artios to receive USD20 million up-front payment in addition to near term research funding to support the
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies
Artios Pharma, Inc.April 7, 2021 GMT
Novartis to leverage Artios’ discovery platform to identify DDR targets for use with Novartis’ proprietary radioligand therapies.
Artios to receive US$20 million up-front payment in addition to near term research funding to support the collaboration.
Artios eligible to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones in addition to royalty payments.
CAMBRIDGE, United Kingdom and NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting synthetic lethality to develop a broad pipeline of precision medicines for the treatment of cancer, today announced a global research collaboration with Novartis to discover and validate next generatio
Novartis, Artios Pharma Target Cancer in Up-to-$1.3B DDR Collaboration
April 7, 2021
Share
Artios Pharma CEO Niall Martin, PhD
Novartis has agreed to identify and validate next-generation DNA Damage Response (DDR) targets for precision cancer treatments using Artios Pharma’s discovery platform, through a collaboration that could generate more than $1.3 billion for Artios.
The companies plan to discover and validate targets that enhance Novartis’ Radioligand Therapies (RLTs) through a three-year research collaboration. Novartis will select up to three exclusive DDR targets, and receive worldwide rights on these targets for use with its RLTs, which are designed to deliver targeted radiation to a specific subset of cancer cells with minimal effect on surrounding healthy cells.
Share this article
Share this article
SAN FRANCISCO, March 2, 2021 /PRNewswire/ Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, announced today that AbbVie, a leading global biopharmaceutical company, has purchased an exclusive right to acquire Mitokinin following completion of IND enabling studies on Mitokinin s lead PINK1 compound. Based on technology discovered at UCSF by Mitokinin co-founders Nicholas Hertz and Kevan Shokat, Mitokinin moved into MBC BioLabs San Francisco in September 2017 with Series A funding from a syndicate led by Mission BioCapital.
Mitokinin s novel PINK1 compounds selectively increase the activity of PINK1, a master regulator of mitochondrial quality control that is genetically linked to Parkinson s disease.
Posted on 394
Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, today announced the appointment of Nikola Trbovic, Ph.D., Executive Director and Partner at Pfizer Ventures, as a member of its Board of Directors.
“Nikola’s expertise in R&D and corporate finance will be an asset to Palleon, and we are very pleased to welcome him to the Board. Nikola will replace Bill Burkoth, who we would like to thank for the valuable support and guidance that he has given to Palleon over the years,” said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. “This is an exciting time of growth for the company as our lead program, an enzymatic sialoglycan degrader for T cell exhaustion in cancer, is expected to enter clinical testing later this year. We look forward to working closely with Nikola as we advance our programs to first